PUREfi Wealth LLC Grows Position in Eli Lilly and Company $LLY

PUREfi Wealth LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 70.4% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 2,190 shares of the company’s stock after acquiring an additional 905 shares during the quarter. Eli Lilly and Company accounts for approximately 1.4% of PUREfi Wealth LLC’s investment portfolio, making the stock its 13th largest holding. PUREfi Wealth LLC’s holdings in Eli Lilly and Company were worth $1,707,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Brighton Jones LLC raised its holdings in shares of Eli Lilly and Company by 22.0% in the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC grew its position in Eli Lilly and Company by 2.8% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Perkins Coie Trust Co grew its position in Eli Lilly and Company by 8.6% in the first quarter. Perkins Coie Trust Co now owns 6,571 shares of the company’s stock worth $5,427,000 after acquiring an additional 521 shares in the last quarter. Sivia Capital Partners LLC grew its position in Eli Lilly and Company by 13.4% in the first quarter. Sivia Capital Partners LLC now owns 2,092 shares of the company’s stock worth $1,728,000 after acquiring an additional 248 shares in the last quarter. Finally, TB Alternative Assets Ltd. purchased a new position in Eli Lilly and Company in the first quarter worth $487,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Daniel Skovronsky bought 1,000 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, with a total value of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO David A. Ricks bought 1,632 shares of the firm’s stock in a transaction on Tuesday, August 12th. The shares were acquired at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on LLY shares. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. UBS Group cut their target price on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 20th. Leerink Partners reiterated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Finally, Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Eli Lilly and Company has a consensus rating of “Moderate Buy” and an average price target of $938.94.

Eli Lilly and Company Price Performance

LLY stock opened at $840.46 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The company has a market cap of $795.46 billion, a P/E ratio of 54.93, a PEG ratio of 1.17 and a beta of 0.47. The firm has a 50-day moving average of $734.60 and a 200 day moving average of $765.44. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the prior year, the firm earned $3.92 earnings per share. Eli Lilly and Company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.